Jump to content Jump to main menu Jump to sub menu

Latest News

23 May 2013 - Healthcare at Home joins QED in OrphanReach alliance

Healthcare at Home Ltd, Europe’s leading provider of home-based healthcare and patient support company has joined QED Clinical Services Ltd, a global full service clinical research organization (CRO), as part of the strategic alliance, OrphanReach.

OrphanReach is a strategic alliance that pools the vast experience, heritage, and capabilities of both Healthcare at Home and QED Clinical Services. OrphanReach is built to support the launch of the growing number of “Rare and Orphan” products throughout the world. With the increasing amount of rare and orphan products in the global pipeline and the unique demands and needs of biopharmaceutical companies bringing such products through clinical development to launch, the OrphanReach alliance serves a unique market with a unique proposition.

OrphanReach has been created in order to provide the biopharmaceutical industry with the ultimate product lifecycle solution including clinical support and integrated patient management. By fusing the core capabilities, experience and skills of both organisations, OrphanReach can work with clients to deliver the most integrated clinical development programme and launch plan within rare and orphan conditions. OrphanReach enables biopharmaceutical clients to access and retain the optimum number of patients throughout a clinical trial programme wherever they are in the world. It provides the ability to recruit and retain these patients at unrivalled compliance levels because of the unique shared capabilities of Healthcare at Home and QED Clinical Services. The clinical development plan can then be supported with synergistic “named patient programmes”, “key opinion leader development activities”, “patient association plans” and “innovative channel strategies,” all of which have robust health informatics at their core.

Healthcare at Home has been operating within the “rare and orphan” markets for over 15 years and has supported the launch of many products across Europe including running homecare arms in clinical trials, ensuring patients can access medicines before commercial launch as well as providing a unique channel strategy and well harnessed key opinion leader network for launch. By taking the treatment direct to the patient the health informatics and insight is significant for the biopharmaceutical partners.

QED has demonstrated for more than 10 years that its unique global delivery model is well suited to support clinical trials involving only few patients distributed over many countries. With experience in 70+ rare disease projects a wealth of expertise within the team significantly contributes to adequately address the particular challenges in the orphan drug development domain.

Commenting on the alliance Mike Gordon, Chief Executive Officer for Healthcare at Home, said: “OrphanReach will solve some key problems facing biopharmaceutical companies launching new medicines. It will ensure that pre-launch plans are data rich, evidence based and patient focused. It will ensure that market access is optimized and product launches are as successful as can be.”

Thomas Ogorka, Chief Executive Officer of QED Clinical Services, commented: “We are delighted to be working alongside Healthcare at Home in this strategic alliance. We have a rich track record of optimizing clinical development within rare and orphan markets and this alliance enables QED to take the range of services we can offer to a new level but more importantly support clients in a far deeper and more strategic way.”